Assessment of safety and efficacy of Saroglitazar in patients with diabetic dyslipidemia
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 8867-8871
Abstract
Background: Cardiovascular diseases (CVD) are the primary cause of morbidity and mortality among individuals with T2D, where cardiovascular risk tends to be primarily influenced by dyslipidemia. The present study assessed efficacy of Saroglitazar in patients with diabetic dyslipidemia.Materials & Methods: 84 patients with type II diabetes mellitus of both genders were selected. Patients were treated with Saroglitazar 4 mg once daily. All parameters such as serum fasting blood glucose, post-prandial blood glucose level (PPBG), glycated hemoglobin (HbA1c), blood urea, serum creatinine, S.G.O.T, S.G.P.T and lipid profile were determined at baseline, 12 weeks and 48 weeks.
Results: Out of 84 patients, males were 50 and females were 34. The mean FPG was 154.2, 128.5 and 118.4, PPG was 232.6, 170.1 and 158.5, HbA1C was 8.0, 7.6 and 6.9, triglyceride level was 608.4, 206.4 and 222.4, total cholesterol was 312.2, 244.7 and 172.1, non- HDL- C was 272.8, 197.6 and 124.3, LDL- C was 163.6, 114.8 and 102.17, HDL- C was 39.4, 40.1 and 40.5, creatinine was 0.6, 0.7 and 0.7, CPK was 72.3, 69.6 and 66.3, SGOT was 44.6, 40.3 and 38.3, SGPT was 32.2, 36.4 and 35.4 at baseline, 12 weeks and 48 weeks respectively. The difference was significant (P<0.05).
Conclusion: Saroglitazar is a very effective with sufficient safety therapeutic agent in diabetic dyslipidemia patients with very high triglycerides level.
Keywords:
- Article View: 4
- PDF Download: 14